je.st
news
Home
› Premarket Biotech Digest: Gilead Gets A Boost, Zafgen's Beloranib Program, Relypsa Gets FDA Nod
Premarket Biotech Digest: Gilead Gets A Boost, Zafgen's Beloranib Program, Relypsa Gets FDA Nod
2015-10-24 12:08:16| Biotech - Topix.net
Parkinson's is very difficult to diagnose- in fact, there's no real diagnostic test for PD. A doctor usually looks at your medical history, maybe some changes in behavior, and may conduct blood tests and scans to eliminate other diseases.
Tags: program
boost
digest
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||